February 25, 2013
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing
drug candidates for the prevention and treatment of cancer, today announced that William B. White
voluntarily resigned from Helix’s board of directors with effect from February 22, 2013.
Commenting on the resignation, Mario Gobbo, Chairman of the Board of Helix said, “Over the past eleven
months, Bill has provided valuable contributions to the board while it has made several key business and
strategic decisions, and we thank him in particular for his able stewardship during his service as Chairman of
the Board for ten of those months. We regret his departure and wish Bill well in the future.”
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The
company is actively developing innovative products for the prevention and treatment of cancer based on its
proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the
Helix BioPharma Corp.
Tel: 905 841-2300